Medicine against parasites like Tapeworms and Giardia, contains a substance that kills Prostate- and colon cancer.
Cancer researchers at the University of Bergen (UiB) have in the recent years experienced with hundreds of known drugs, to see how they influence cancer cells.
Recently they found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.
“We discovered that this specific substance is blocking the signalling pathway in the cancer cells, and make them stop growing. It is not often that researchers discover a substance that targets specific molecules as precisely as this one, ” says Professor Karl-Henning Kalland at the Department of Clinical Science, at UiB. He is the leader of the Kalland´s Research Group.
The study is published in Nature Chemical Biology.
The researchers Yi Qu and Xisong Ke at Kalland team saw that the cells in prostate- and colon cancer contain high amounts of activated Beta-catenin. Activation of this protein makes the cells go amok and divides at high tempo. In addition, Beta-catenin makes the cancer cells more resistant and more able for survival.
In the study, Qu and Ke discovered that it was the substance NTZ (nitazoxanide), a well known and approved anti-parasite drug, that decompose the activated Beta-catenin.
“We are the first researchers who have mapped the complex molecular mechanisms involved in this process,” Kalland says.
Recycling old medicines
Experiments with well-known drugs show that a medicine may have different and unknown targets in the cells.
“The advantage of testing already approved drugs, is that we know they work in the human body and have no serious side effects, which means that a future treatment may happen quicker,” Kalland explains.
Strengthen the immune system
NTZ attacks cancer celles by hindering the activated Beta-catenin. It appears that this hindering also stimulates central parts of the immune system, that attacks cancer cells.
“At the moment, we are working on how to strengthen our on going immune therapy against prostate cancer by using the mechanisms we discovered of the NTZ,” Kalland says.
Kalland and his research-team is in the first phase in a clinical trial using immune therapy against prostate cancer.
Learn more: Tapeworm drug fights Prostate Cancer
The Latest on: Immune therapy
- New and Emerging Immunotherapy Combos for Advanced RCC: Finding the Right Treatmentson August 16, 2019 at 10:52 am
Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma (RCC). For oncologists, the challenge now ...
- Buy Merck Stock Because Its Immunotherapy Drug Is a Game-Changer, Analyst Sayson August 16, 2019 at 6:17 am
https://www.barrons.com/articles/merck-stock-keytruda-51565961204 Merck’s immunotherapy drug Keytruda is a game changer. That’s the message in a report out late Thursday from SVB Leerink analyst Diana ...
- XYLONIX SIGNS MOU WITH BIOGEMEX TO CO-DEVELOP A PREDICTIVE CANCER IMMUNOTHERAPY TREATMENT RESPONSE DIAGNOSTICon August 15, 2019 at 10:30 pm
XYLONIX SIGNS MOU WITH BIOGEMEX TO CO-DEVELOP A PREDICTIVE CANCER IMMUNOTHERAPY TREATMENT RESPONSE DIAGNOSTIC XDX-01, a novel, point-of-care pre-treatment diagnostic, has completed early ...
- Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trialon August 15, 2019 at 10:30 am
IRVINE, Calif., Aug. 14, 2019 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing ...
- Merck's Cancer Immunotherapy Keytruda Continues to Aid Growthon August 15, 2019 at 5:30 am
The demand for checkpoint inhibitors, especially those targeting PD-1 and PD-L1, has risen significantly in the past couple of years. Cancer therapies that target either PD-1 or PD-L1 can stop ...
- Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapyon August 15, 2019 at 4:49 am
EMERYVILLE, Calif., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of immunotherapies to fight ...
- Combinations Mark Future of Immunotherapy in Multiple Myelomaon August 14, 2019 at 11:57 am
The emergence of monoclonal antibodies, immunomodulatory agents (iMids), immunotoxins, bispecific T-cell engagers (BiTEs), and CAR T-cell therapies will redefine multiple myeloma treatment, said ...
- What is immunotherapy anyway? What you need to know about this exciting cancer treatmenton August 14, 2019 at 6:56 am
One of the most exciting advancements in cancer treatment in recent years is immunotherapy, which uses the body's own immune system to fight cancer. Many people became aware of immunotherapy when ...
- Roche Sets An Immunotherapy First With Tecentriq Combination: Looks To Increase Saleson August 13, 2019 at 12:13 pm
Roche established a positive finding using a Tecentriq combination to target a hard to treat first line advanced bladder cancer patients. Tecentriq given in combination with platinum-based ...
- New T cell detection method promises personalized immunotherapy for melanomason August 12, 2019 at 6:42 am
An important new study shows that better T cell detection is now possible using revolutionary technology. T cells are a type of lymphocyte, which in turn belongs to the diverse family of immune cells.
via Google News and Bing News